Although myosin inhibitors, particularly mavacamten, have demonstrated clinical benefit in patients with hypertrophic cardiomyopathy by targeting hypercontractility and improving diastolic function [141,142], their role in valvular aortic stenosis remains unexplored. The gene discussed is MYH14; the disease is hypertrophic cardiomyopathy.